Classification of vasculitis: EMA classification using CHCC 2012 definitions

Abdulkader, Rita; Lane, Suzanne; Scott, David G. I.; Watts, Richard A.

doi:10.1136/annrheumdis-2013-203511

Cited by 42 publications

(38 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients were classified using the European Medicines Agency algorithm . The performance of this well‐validated tool for the classification of systemic vasculitis is similar when used with either the 1994 or the 2012 Chapel Hill Consensus Conference definitions . Two physicians experienced in the treatment of systemic vasculitis (JHS and JUH) classified the patients independently (patients were excluded in cases of disagreement if the researchers did not reach agreement when discussing these cases).…”

Section: Methodsmentioning

confidence: 99%

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA‐Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center

Schirmer

Wright

Herrmann

et al. 2016

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA‐Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center

Schirmer

Wright

Herrmann

et al. 2016

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Exclusion criteria were AAV induced by cocaine or other drugs, and/or anti–glomerular basement membrane (anti‐GBM) positivity . Patients were classified using the European Medicines Agency classification as having GPA, MPA, or eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (EGPA) . GPA was considered to be localized when the disease was restricted to the upper and/or lower respiratory tract, as previously defined by the European League Against Rheumatism/European Vasculitis Study Group guidelines .…”

Section: Methodsmentioning

confidence: 99%

HLA–DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Cohort Study

Hilhorst

Arndt

Kemna

et al. 2016

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective The antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAVs) form a group of small‐vessel vasculitides with systemic involvement. Although the etiology of AAVs remains largely unknown, both genetic and environmental factors have been implicated. Recently, certain alleles in the HLA–DPB1 region on chromosome 6 were shown to be associated with proteinase 3 (PR3)–ANCA–positive AAV but not with myeloperoxidase (MPO)–ANCA–positive AAV. The aim of this study was to investigate whether different alleles in the HLA–DPB1 region have clinical and/or prognostic implications in AAV. Methods One hundred seventy‐four patients with a diagnosis of AAV were recruited at the Maastricht University Medical Centre between 2000 and 2009. Seventeen different HLA–DPB1 alleles were determined using the restriction fragment length polymorphism technique. A validation cohort of 170 AAV patients from the Vasculitis Centre of Luebeck/Bad Bramstedt was included. Results In the initial cohort, the distribution of HLA–DPB1 alleles was significantly different between PR3‐ANCA–positive compared with MPO‐ANCA–positive AAV patients, ANCA‐negative AAV patients, and healthy controls. Importantly, HLA–DPB1*04:01 was present in 90% of PR3‐ANCA–positive AAV patients compared with 63% of MPO‐ANCA–positive AAV patients, 58% of ANCA‐negative patients, and 63% of healthy controls. Patients homozygous for HLA–DPB1*04:01 had relapses more often compared with heterozygous patients and noncarrier patients. This association persisted after correction for ANCA subtype and diagnosis. In the validation cohort, patients homozygous for HLA–DPB1*04:01 and those heterozygous for HLA–DPB1*04:01 had relapses more often compared with noncarrier patients. When both patient cohorts were merged (n = 344), homozygous patients relapsed most often, followed by heterozygous patients and noncarrier patients. Conclusion Carriage of HLA–DPB1*04:01 in patients with AAV is significantly associated with an increased risk of relapse compared with HLA–DPB1*04:01–negative patients, irrespective of ANCA status or clinical AAV entity.

show abstract

“…Barring a single patient who had to be excluded from the analysis, all MPA patients were also reclassified in the same diagnostic category. The new classification algorithm has been shown to have good correlation when either the original (1994) or the revised (2012) Chapel Hill definitions were used in the algorithm . Similar results were found in our study.…”

Section: Discussionmentioning

confidence: 99%

Validation of the consensus methodology algorithm for the classification of systemic necrotizing vasculitis in Indian patients

et al. 2013

View full text Add to dashboard Cite

show abstract

Classification of vasculitis: EMA classification using CHCC 2012 definitions

Cited by 42 publications

References 7 publications

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA‐Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA‐Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center

HLA–DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Cohort Study

Validation of the consensus methodology algorithm for the classification of systemic necrotizing vasculitis in Indian patients

Contact Info

Product

Resources

About